Stay updated with breaking news from Checkmate 214. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.
An overview of the treatment protocol for patients with advanced RCC who are receiving IO/TKI or IO/IO combination therapy.
Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.
Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.